PTPI News and Press, Petros Pharmaceuticals Inc. From 12/12/23

2023-12-12 11:10:11 ET DENVER, Colo., Dec 12, 2023 ( www.247marketnews.com )- Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) reported, this morning, that it finished a Human Factors Study, to assess the technology component developed to facilitate patient’s access to its erectile dy...

Human Factor Study represents important component of FDA requirements for technology to pave way for STENDRA OTC approval NEW YORK, NY / ACCESSWIRE / December 12, 2023 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI), a company focused on expanding consumer access to medication through over-th...

Idea Evolver is the only provider to successfully complete Actual Use Trial for FDA review for Rx-to-OTC Switch Approval NEW YORK, NY / ACCESSWIRE / December 5, 2023 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the- c...

New AI/machine learning tool designed to help potential users more effectively self-select in the effort to make STENDRA the first erectile dysfunction (ED) medication available OTC Petros in discussions with third-party technology partners NEW YORK, NY / ACCESSWIRE / October 30, 2023 / ...

Important step towards STENDRA potentially becoming the first erectile dysfunction medication to successfully achieve OTC Status NEW YORK, NY / ACCESSWIRE / October 19, 2023 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through o...

Company well positioned to continue collaboration with FDA toward pursuit of OTC pathway for STENDRA NEW YORK, NY / ACCESSWIRE / October 4, 2023 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over the counter (OTC) nonprescr...

NEW YORK, NY / ACCESSWIRE / September 28, 2023 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI), a company focused on expanding consumer access to medication through over the counter (OTC) pathway, announces today that Fady Boctor, President and Chief Commercial Officer, will present a corporate ove...

NEW YORK, NY / ACCESSWIRE / September 11, 2023 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over the counter (OTC) pathway provides the below Letter to Shareholders: To our valued shareholders, As we approach the fourth quar...

NEW YORK, NY / ACCESSWIRE / September 6, 2023 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI), a pioneer in expanding consumer access to medication through over the counter (OTC) pathways, announces today that Fady Boctor, President and Chief Commercial Officer, will present a corporate overview at...

2023-07-14 10:27:11 ET Petros Pharmaceuticals ( NASDAQ: PTPI ) shares slipped -9.3% in early trading on Friday after the company said it had secured $15M private placement financing. The micro-cap health company said it had it will utilize the funds to advance bringin...